Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Replidyne closes $40mm second round

Executive Summary

Anti-infectives developer Replidyne raised $40mm from its second round of venture financing. New investors TPG Ventures (an affiliate of the Texas Pacific Group), led the round and Perseus-Soros Biopharmaceutical Fund purchased significant amounts of equity. Returning investors HealthCare Ventures, Morgenthaler Ventures, and Sequel Venture Partners also participated.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies